Verrica Pharmaceuticals Inc. (VRCA) stock
VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.56−0.16 (-4.30%)
Close on Nov 13, 2026Market cap $61.16MP/E –Yield –
Verrica Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Verrica Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was -189.2%. For fiscal 2025 it was -50.3%, against -1012.1% the year before. The highest annual figure on record is -50.3% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -50.3% | +961.9 |
| FY2024 | Dec 31, 2024 | -1012.1% | +295.3 |
| FY2023 | Dec 31, 2023 | -1307.5% | −1036.4 |
| FY2022 | Dec 31, 2022 | -271.1% | +21.2 |
| FY2021 | Dec 31, 2021 | -292.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -179.4% | −177.5 |
| Q2 FY2026 | Jun 30, 2026 | -224.4% | −226.0 |
| Q1 FY2026 | Mar 31, 2026 | -192.8% | +90.5 |
| Q4 FY2025 | Dec 31, 2025 | -158.6% | +4551.3 |
| Q3 FY2025 | Sep 30, 2025 | -1.9% | +330.1 |
| Q2 FY2025 | Jun 30, 2025 | 1.6% | +533.0 |
| Q1 FY2025 | Mar 31, 2025 | -283.3% | +954.8 |
| Q4 FY2024 | Dec 31, 2024 | -4709.9% | −3859.6 |
| Q2 FY2024 | Jun 30, 2024 | -332.0% | +5706.5 |
| Q1 FY2024 | Mar 31, 2024 | -531.4% | +17276.7 |
| Q4 FY2023 | Dec 31, 2023 | -1238.1% | +7485.4 |
| Q3 FY2023 | Sep 30, 2023 | -850.3% | −851.3 |
| Q2 FY2023 | Jun 30, 2023 | -6038.5% | −1287.1 |
| Q1 FY2023 | Mar 31, 2023 | -17808.1% | −15842.9 |
| Q4 FY2022 | Dec 31, 2022 | -8723.5% | −8715.7 |
| Q3 FY2022 | Sep 30, 2022 | 1.0% | – |
| Q2 FY2022 | Jun 30, 2022 | -4751.4% | – |
| Q1 FY2022 | Mar 31, 2022 | -1965.2% | – |
| Q1 FY2021 | Mar 31, 2021 | -7.8% | – |
See a number that looks wrong?